Mimpara, known generically as cinacalcet, is a medication primarily used to treat secondary hyperparathyroidism (overactivity of the parathyroid glands) in patients with chronic kidney disease on dialysis, and hypercalcemia (high calcium levels in the blood) in patients with parathyroid carcinoma. It operates by directly lowering the levels of parathyroid hormone (PTH), calcium, and phosphorous in the body, helping to maintain a balance that is often disrupted in these conditions. Mimpara works by mimicking the action of calcium on the parathyroid gland, thereby decreasing the production of PTH. This medication is typically administered in tablet form and the dosage is adjusted based on the patient's response and laboratory results. It is important for patients to follow their healthcare provider's instructions closely when taking Mimpara to ensure its effectiveness and minimize potential side effects.